Literature DB >> 2049309

Follicular lymphomas: assessment of prognostic factors in 127 patients followed for 10 years.

Y Bastion1, F Berger, P A Bryon, P Felman, M Ffrench, B Coiffier.   

Abstract

Response to treatment, histologic progression, and survival of 127 patients with follicular lymphoma were analyzed according to histologic, clinical, and biological parameters. Histologic parameters were percentage of large cells (less than 10%, 41 patients; 10-25%, 38 patients; 25-50%, 11 patients; greater than or equal to 50%, 30 patients), percentage of diffuse areas, presence of intrafollicular proliferation or fibrosis, and mitotic scale. Eighty percent of the patients achieved complete remission (CR) with radiotherapy for localized stages and various chemotherapy regimens for disseminated stages. Three patients did not respond to treatment, and 23 were in partial remission (PR) at the end of treatment. Median survival time was 9.25 years. A constant death rate of 8% per year was observed without plateau. Histologic progression was observed in 32 patients; it occurred at a constant rate during the first six years and plateaued thereafter. Factors associated with low response rate were stage IV, B symptoms, high tumor mass, and two or more extranodal sites. Factors associated with histologic progression were bone marrow involvement and two or more extranodal sites. Factors associated with poor survival were advanced stage, two or more extranodal sites, bone marrow involvement, high lactate dehydrogenase level, and absence of interfollicular fibrosis. The percentages of large cells and diffuse areas had no influence on prognosis, nor had the type of treatment. Median survival has not been reached for CR patients and was four years for PR patients (P less than 0.0001). The LNH-84 prognostic index for aggressive lymphomas, based on tumor mass, number of extranodal sites, stage, and LDH level, is a clear-cut indicator of prognosis in follicular lymphomas too.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1991        PMID: 2049309     DOI: 10.1007/978-1-4899-7305-4_19

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  7 in total

Review 1.  Clinical and molecular prognostic factors in follicular lymphoma.

Authors:  Andrew J Davies
Journal:  Curr Oncol Rep       Date:  2006-09       Impact factor: 5.075

Review 2.  Low-grade lymphomas: new entities and treatment concepts.

Authors:  F B Hagemeister
Journal:  Med Oncol       Date:  1995-09       Impact factor: 3.064

3.  Predictive value of prognostic indices in patients with follicular lymphomas.

Authors:  M Radojkovic; S Ristic; M Colovic; B Mihaljevic; V Cemerikic-Martinovic
Journal:  Med Oncol       Date:  2006       Impact factor: 3.064

4.  A British National Lymphoma Investigation randomised trial of single agent chlorambucil plus radiotherapy versus radiotherapy alone in low grade, localised non-Hodgkins lymphoma.

Authors:  S M Kelsey; A C Newland; G V Hudson; A M Jelliffe
Journal:  Med Oncol       Date:  1994       Impact factor: 3.064

5.  Primary follicular lymphoma of the common bile duct mimicking cholangiocarcinoma.

Authors:  Khaled Youssef Elbanna; Saeed Al-Shieban; Fahad Azzumeea
Journal:  J Clin Imaging Sci       Date:  2014-12-31

6.  Radiotherapy as an effective treatment modality for follicular lymphoma: a single institution experience.

Authors:  Seo Hee Choi; Jaeho Cho; Jin Seok Kim; June-Won Cheong; Chang-Ok Suh
Journal:  Radiat Oncol J       Date:  2015-12-30

Review 7.  Approach to Cutaneous Lymphoid Infiltrates: When to Consider Lymphoma?

Authors:  Yann Vincent Charli-Joseph; Michelle Gatica-Torres; Laura Beth Pincus
Journal:  Indian J Dermatol       Date:  2016 Jul-Aug       Impact factor: 1.494

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.